Jaguar Health Reports Q3 2026 Results; Revenue Down 24% YoY as Company Transitions to Licensing Model
Jaguar Health reported Q3 2026 total revenue of $2.34 million, down 24% year-over-year from $3.08 million, as the company transitioned to a licensing model following its January 2026 agreement with Future Pak for Mytesi and Canalevia-CA1 U.S. commercialization. Net loss improved to $5.83 million from $9.65 million in Q3 2025, while the company significantly reduced outstanding debt by $10.1 million during the quarter. The company expects to file an NDA for crofelemer powder for oral solution for microvillus incl...
Key takeaways
Revenue mix shifted to licensing: product revenue fell to $551,000 from $3.04 million in Q3 2025 while license and grant revenue rose to $1.79 million from $42,000, reflecting recognition of upfront payments under the January 2026 Future Pak agreement for Mytesi and Canalevia-CA1 U.S. commercialization.
The company dissolved its salesforce and moved to a licensing model in which product revenues now flow to Future Pak, with strategic focus shifting from commercial sales to research and development.
Operating expenses were reduced by $2.0 million in the quarter, partially offsetting lower revenues and narrowing the operating loss to $6.02 million from $7.24 million.
Outstanding debt was reduced by $10.1 million during Q3 2026, including full repayment of the Streeterville New Note through a stock exchange transaction.
Non-GAAP Recurring EBITDA loss improved to $5.03 million from $9.03 million in the prior-year quarter.
The company issued no full-year revenue or earnings guidance; the only forward-looking item disclosed is the planned mid-2027 NDA filing for crofelemer powder for oral solution for microvillus inclusion disease.
An investor webcast to discuss Q3 2026 financials and company updates is scheduled for November 17, 2026 at 8:30 a.m. Eastern.
Key metrics
Disclosure changes
- Business model transition
Effective January 12, 2026, Jaguar entered a U.S. commercial licensing agreement with Future Pak, making Future Pak the exclusive U.S. marketer for Mytesi and Canalevia-CA1. Jaguar now operates as a distribution entity focused on R&D for its crofelemer powder-for-oral-solution formulation for rare-disease indications.
Fundamental shift in business model affecting revenue recognition, operating expenses, and strategic focus - Debt reduction
Company significantly reduced outstanding debt balance by $10.1 million in Q3 2026, including full repayment and cancellation of the Streeterville New Note through a stock exchange transaction.
Material improvement in balance sheet and reduction in financial obligations - Revenue concentration
License revenues from the $16 million upfront payment and $3 million early termination payment under the Future Pak agreement were recognized in Q1 2026. Total deferred revenue as of September 30, 2026 was $425,000.
Change in revenue recognition timing and composition
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow JAGX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.